Literature DB >> 2984980

Controlled trial of enviroxime against natural rhinovirus infections in a community.

F D Miller, A S Monto, D C DeLong, A Exelby, E R Bryan, S Srivastava.   

Abstract

The therapeutic effect of intranasally administered enviroxime was tested against naturally occurring common colds. The double-blind evaluation was carried out in Tecumseh, Mich., during a period when rhinoviruses are usually the principal pathogen. Rhinovirus transmission followed the typical pattern during this period of study. Although there were trends indicating greater therapeutic effectiveness for enviroxime when certain nasal symptoms were considered, there were no consistent statistically significant differences between treated and untreated groups. Results were unchanged when illnesses in different periods or associated with rhinovirus isolation were examined. It was concluded that no therapeutic effect of enviroxime was demonstrated.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2984980      PMCID: PMC176213          DOI: 10.1128/AAC.27.1.102

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  The Tecumseh study of respiratory illness. IV. Prevalence of rhinovirus serotypes, 1966-1969.

Authors:  A S Monto; J J Cavallaro
Journal:  Am J Epidemiol       Date:  1972-11       Impact factor: 4.897

2.  A computer program for testing average partial association in three-way contingency tables (PARCAT).

Authors:  J R Landis; M M Cooper; T Kennedy; G G Koch
Journal:  Comput Programs Biomed       Date:  1979-05

3.  The activity of enviroxime against rhinovirus infection in man.

Authors:  R J Phillpotts; R W Jones; D C Delong; S E Reed; J Wallace; D A Tyrrell
Journal:  Lancet       Date:  1981-06-20       Impact factor: 79.321

4.  Prophylactic activity of intranasal enviroxime against experimentally induced rhinovirus type 39 infection.

Authors:  F G Hayden; J M Gwaltney
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

5.  Inhibition of rhinovirus replication in in organ culture by a potential antiviral drug.

Authors:  D C DeLong; S E Reed
Journal:  J Infect Dis       Date:  1980-01       Impact factor: 5.226

6.  Therapeutic activity of enviroxime against rhinovirus infection in volunteers.

Authors:  R J Phillpotts; J Wallace; D A Tyrrell; V B Tagart
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

  6 in total
  16 in total

1.  Phosphatidylinositol 4-kinase III beta is essential for replication of human rhinovirus and its inhibition causes a lethal phenotype in vivo.

Authors:  Catherine Spickler; Julie Lippens; Marie-Kristine Laberge; Sophie Desmeules; Édith Bellavance; Michel Garneau; Tim Guo; Oliver Hucke; Pieter Leyssen; Johan Neyts; Fréderic H Vaillancourt; Anne Décor; Jeff O'Meara; Michael Franti; Annick Gauthier
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

Review 2.  Chemotherapy of rhinovirus colds.

Authors:  S J Sperber; F G Hayden
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

Review 3.  Antiviral therapy with small particle aerosols.

Authors:  V Knight; B Gilbert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-12       Impact factor: 3.267

Review 4.  Human rhinoviruses.

Authors:  Samantha E Jacobs; Daryl M Lamson; Kirsten St George; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2013-01       Impact factor: 26.132

5.  Antirhinovirus activity of purine nucleoside analogs.

Authors:  E De Clercq; R Bernaerts; D E Bergstrom; M J Robins; J A Montgomery; A Holy
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

6.  Discovery of itraconazole with broad-spectrum in vitro antienterovirus activity that targets nonstructural protein 3A.

Authors:  Qianqian Gao; Shilin Yuan; Chao Zhang; Ying Wang; Yizhuo Wang; Guimei He; Shuyi Zhang; Ralf Altmeyer; Gang Zou
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

7.  Activity against rhinoviruses, toxicity, and delivery in aerosol of enviroxime in liposomes.

Authors:  P R Wyde; H R Six; S Z Wilson; B E Gilbert; V Knight
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

8.  Enterovirus A71 antivirals: Past, present, and future.

Authors:  Jun Wang; Yanmei Hu; Madeleine Zheng
Journal:  Acta Pharm Sin B       Date:  2021-08-20       Impact factor: 14.903

9.  The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus.

Authors:  B A Heinz; L M Vance
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

10.  Potential use of antiviral agents in polio eradication.

Authors:  Armando M De Palma; Gerhard Pürstinger; Eva Wimmer; Amy K Patick; Koen Andries; Bart Rombaut; Erik De Clercq; Johan Neyts
Journal:  Emerg Infect Dis       Date:  2008-04       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.